Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia

Aim. Current clinical recommendations accentuate current methods for the diagnosis and treatment of irritable bowel syndrome (IBS).

Key points. IBS is a functional bowel disorder manifested with recurrent, at least weekly, abdominal pain with the following attributes (any two leastwise): link to defecation, its frequency or stool shape. The symptoms are expected to persist for at minimum three months in a total six-month follow-up. Similar to other functional gastrointestinal (GI) disorders, IBS can be diagnosed basing on the patient symptoms compliance with Rome IV criteria, provided the absence of potentially symptom-causative organic GI diseases. Due to challenging differential diagnosis, IBS can be appropriately established per exclusionem, with pre-examination as follows: general and biochemical blood tests; tissue transglutaminase IgA/IgG antibody tests; thyroid hormones test; faecal occult blood test; hydrogen glucose/ lactulose breath test for bacterial overgrowth; stool test for enteric bacterial pathogens and Clostridium difficile A/B toxins; stool calprotectin test; abdominal ultrasound; OGDS, with biopsy as appropriate; colonoscopy with biopsy. The IBS sequence is typically wavelike, with alternating remissions and exacerbations often triggered by psychoemotional stress. Treatment of IBS patients includes dietary and lifestyle adjustments, various-class drug agents prescription and psychotherapeutic measures.

Conclusion. Adherence to clinical recommendations can facilitate timely diagnosis and improve medical aid quality in patients with different clinical IBS variants.

1. El-Serag H.B., Olden K., Bjorkman D. Healthrelated quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16(6):1171–85. DOI: 10.1046/j.1365-2036.2002.01290.x

2. Akehurst R.L., Brazier J.E., Mathers N., O’Keefe C., Kaltenthaler E., Morgan A., et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20(7):455– 62. DOI: 10.2165/00019053-200220070-00003

3. Ivashkin V.T., Poluektova Ye.A. Combination of functional dyspepsia syndrome and irritable bowel syndrome Rus J Gastroenterol Hepatol Coloproctol. 2011;21(4):75–81 (In Russ.).

4. Yarandi S.S., Christie J. Functional Dyspepsia in Review: Pathophysiology and Challenges in the Diagnosis and Management due to Coexisting Gastroesophageal Reflux Disease and Irritable Bowel Syndrome. Gastroenterol Res Pract. 2013. DOI: 10.1155/2013/351086

5. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;S0016-5085. DOI: 10.1053/j.gastro.2016.02.031

6. Nagasako C.K., Montes C.G., Lorena S.L.S., Mesquita M.A. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. RevEspEnfermDig. 2016;108(2):59–64. DOI: 10.17235/reed.2015.3979/2015

7. Cho H.S., Park J.M., Lim C.H., Cho Y.K., Lee I.S., Kim S.W., et al. Anxiety, depression and quality of life in patients with irritable bowel syndrome. Gut Liver. 2011;5(1):29–36. DOI: 10.5009/gnl.2011.5.1.29

8. Corsetti M., Whorwell P.J. Managing irritable bowel syndrome in primary care. Practitioner. 2015;259(1783):21-4, 2-3.

9. Bharadwaj S., Barber M.D., Graff L.A., Shen B. Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle. Gastroenterol Rep (Oxf). 2015;3(3):185–93. DOI: 10.1093/gastro/gov010

10. Issa B., Morris J., Whorwell P.J. Abdominal distension in health and irritable bowel syndrome: The effect of bladder filling. NeurogastroenterolMotil. 2018;30(11). DOI: 10.1111/nmo.13437

11. Rational drug therapy for organic digestive diseases. A practitioner’s guide. Edited by V.T. Ivashkin. Moscow. Izdatelstvo Literra. 2003.

12. Cash B.D., Schoenfeld P., Chey W.D. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97(11):2812–9. DOI: 10.1111/j.1572-0241.2002.07027.x

13. Menees S.B., Kurlander J., Goel A., Powell C., Chey W. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology. 2014;146(5):S194. DOI: 10.1016/S0016-5085(14)60683-1

14. Menees S.B., Powell C., Kurlander J., Goel A., Chey W.D. A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS. Am J Gastroenterol. 2015;110(3):444–54. DOI: 10.1038/ajg.2015.6

15. Irvine A.J., Chey W.D., Ford A.C. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am J Gastroenterol. 2016;112(1):65–76. DOI: 10.1038/ajg.2016.466

16. Koh S.J., Lee D.H., Lee S.H., Park Y.S., Hwang J.H., Kimet J.W., et al. Incidence and Risk Factors of Irritable Bowel Syndrome in Community Subjects with Cultureproven Bacterial Gastroenteritis. Korean J Gastroenterol. 2012;60(1):13–8. DOI: 10.4166/kjg.2012.60.1.13

17. Longstreth G.F., Chen Q., Wong C., Yao J.F. Increased Systemic Antibiotic Use and Clostridium difficile Infection Among Outpatients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2018;16(6):974–6. DOI: 10.1016/j.cgh.2017.11.004

18. Ford A.C., Spiegel B.R., Talley N.J., Moayyedi P. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–86. DOI: 10.1016/j.cgh.2009.06.031

19. Kuchumova S.Yu. Pathogenetic and clinical significance of intestinal microflora in patients with irritable bowel syndrome. Cand. Sci. (Med.) dissertation thesis. Moscow. 2016.

20. Bortoli de N., Tolone S., Frazzoni M., Martinucci I., Sgherri G., Albano E., et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018;31(6):639–48. DOI: 10.20524/aog.2018.0314

21. Chey W.D., Nojkov B., Rubenstein J.H., Dobhan R.R., Greenson J.K., Cash B.D. The Yield of Colonoscopy in Patients With Non-Constipated Irritable Bowel Syndrome: Results From a Prospective, Controlled US Trial. Am J Gastroenterol. 2010;105(4);859–65. DOI: 10.1038/ajg.2010.55

22. Patel P., Bercik P., Morgan D.G., Bolino C., PintosSanchez M.I., Moayyedi P. et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015;50(7):816–23. DOI: 10.3109/00365521.2015.1007079

23. Yang J.-F., Fox M., Chu H., Zheng X., Long Y.-Q., Pohl D., et al. Four-sample lactose hydrogen breath test for diagnosis of lactose malabsorption in irritable bowel syndrome patients with diarrhea. World J Gastroenterol. 2015;21(24):7563–70. DOI: 10.3748/wjg.v21.i24.7563

24. Leeds J.S., Hopper A.D., Sidhu R., Simmonette A., Azadbakht N., Hoggard N., et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8(5):433–8. DOI: 10.1016/j.cgh.2009.09.032

25. Guagnozzi D., Arias ., Lucendo A.J. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther. 2016;43(8):851–62. DOI: 10.1111/apt.13573

26. Ivashkin V.T., Sheptulin А.А., Shifrin O.S., Galimova S.F., Yurmanova Ye.N. Microscopic colitis: clinical forms, diagnostics, treatment. Rus J Gastroenterol Hepatol Coloproctol. 2006;16(6):56–60 (In Russ.).

27. Chachu K.A., Osterman M.T. How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD. Inflamm Bowel Dis. 2016;22(5):1262–74. DOI: 10.1097/MIB.0000000000000726

28. Longstreth G.F., Tieu R.S. Clinically Diagnosed Acute Diverticulitis in Outpatients: Misdiagnosis in Patients with Irritable Bowel Syndrome. Dig Dis Sci. 2016;61(2):578– 88. DOI: 10.1007/s10620-015-3892-5

29. Cuomo R., Barbara G., Andreozzi P., Bassotti G., Casetti T., Grassini M., et.al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest. 2013;43(11):1147–55. DOI: 10.1111/eci.12152

30. Wu C.Y., Chang W.P., Chang Y.H., Li C.P., Chuang C.M. The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study. Int J Colorectal Dis. 2015;30(7):907–12. DOI: 10.1007/s00384-015-2218-6

31. Mathur R., Ko A., Hwang L.J., Low K., Azziz R., Pimentel M. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci. 2010;55(4):1085–9. DOI: 10.1007/s10620-009-0890-5

32. Keller J., Wedel T., Seidl H., Kreis M.E., Andresen V., Preiss J.C., et al. Guideline Irritable Bowel Syndrome: Definition, Pathophysiology, Diagnosis and Therapy. Joint Guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM). Z Gastroenterol. 2011;49(3):374–90. DOI: 10.1055/s-0029-1245993

33. Moayyedi P., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., et al. The effect of dietary intervention on irritable bowel syndrome: a systematic review. Clin Transl Gastroenterol. 2015;6(8):e107. DOI: 10.1038/ctg.2015.21

34. Usai-Satta P., Bellini M., Lai M., Oppia F., Cabras F. Therapeutic Approach for Irritable Bowel Syndrome: Old and New Strategies. Curr Clin Pharmacol. 2018;13(3):164– 72. DOI: 10.2174/1574884713666180807143606

35. Paduano D., Cingolani A., Tanda E., Usai P. Effect of Three Diets (Low-FODMAP, Gluten-free and Balanced) on Irritable Bowel Syndrome Symptoms and Health-Related Quality of Life. Nutrients. 2019;11(7):1566. DOI: 10.3390/nu11071566

36. Johannesson E., Ringström G., Abrahamsson H., Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21(2):600–8. DOI: 10.3748/wjg.v21.i2.600

37. Tuck C.J., Taylor K.M., Gibson P.R., Barrett J.S., Muir J.G. Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by α-galactosidase treatment. Am J Gastroenterol. 2018;113(1):124–34. DOI: 10.1038/ajg.2017.245

38. Ruepert L., Quartero A.O., Wit de N.J., Heijden van der G.J, Rubin G., Muris J.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane Collaboration The Cochrane Library. 2011;8(8):CD003460. DOI: 10.1002/14651858.CD003460.pub3

39. Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schilleret L.R., et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(1):S2–26. DOI: 10.1038/ajg.2014.187

40. Hou X., Chen S., Zhang Y., Sha W., Yu X., Elsawah H., et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783–93. DOI: 10.1007/s40261-014-0233-y

41. Boisson J., Coudert P.YH., Dupuis J., Laverdant C.H., Toulet J. Tolerance de la mebeverine a long terme. Act Ther. 1987;16(4):289–92.

42. Sheptulin A.A., Vize-Khripunova M.A. Comparative of relation of American, German, French and Russian guidelines on irritable bowel syndrome management. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(2):43–9 (In Russ.). DOI: 10.22416/1382-4376-2016-26-2-43-49

43. Jailwala J., Imperiale T.F., Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133(2):136–47. DOI: 10.7326/0003-4819-133-2-200007180-00013

44. Chang F.Y., Lu C.L., Chen C.Y., Luo J.C. Efficacy of dioctahedral smectite in treating patients of diarrheapredominant irritable bowel syndrome. J. Gastroenterol. Hepatol. 2007;22 (12):2266–72. DOI: 10.1111/j.1440-1746.2007.04895.x

45. Menees S.B., Maneerattannaporn M., Kim H.M., Chey W.D. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and metaanalysis. Am J Gastroenterol. 2012;107(1):28–35. DOI: 10.1038/ajg.2011.355

46. Ivashkin V.T., Drapkina O.M., Sheptulin A.A., Shifrin O.S., Poluektova Ye.A., Kuchumova S.Yu. Comparative assessment of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus and Saccharomyces boulardii efficacy at diarrheal variant of irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(2):10–21 (In Russ.).

47. Ivashkin V. T., Drapkina O. M., Sheptulin A. A., Shifrin O. S., Poluektova Ye. A., Kuchumova S. Yu. Comparative efficacy of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus composition and prucalopride in treatment of constipation variant of irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(3):21–32 (In Russ.).

48. Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A., Shifrin O. The Effect of a Multistrain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation-predominant Irritable Bowel Syndrome: A Randomized, Simple-blind, Placebo-controlled Trial. American Journal of Clinical Medicine Research. 2015;3(2):18–23. DOI: 10.12691/ajcmr-3-2-1

49. Guarner F., Sanders M.H., Eliakim R., Fedorak R., Gangl A., Garisch J., et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines, 2017.

50. Ford A.C., Quigley E.M.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61. DOI: 10.1038/ajg.2014.202

51. Tiequn B., Guanqun C., Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a metaanalysis. Intern Med. 2015;54(3):243–9. DOI: 10.2169/internalmedicine.54.2710

52. Skokovic-Sunjic D. Clinical Guide to Probiotic Products Available in Canada. Indications, Dosage Forms, and Clinical Evidence to Date. 2020 (12th Еdition). www.ProbioticChart.ca

53. Steer T., Carpenter H., Tuohy K., Gibson G.R. Perspectives on the role of the human gut microbiota and its modulation by pro- and prebiotics. Nutrition Research Reviews. 2000;13(2):229–54. DOI: 10.1079/095442200108729089

54. Urbanska A.M., Bhathena J., Martoni C., Prakash S. Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc (Min/+) mice. Dig Dis Sci. 2009;54(2):264–73. DOI: 10.1007/s10620- 008-0363-2

55. Schindlbeck N.E., Müller-Lissner S.A. Dietary fiber. Indigestible dietary plant constituents and colon function. Med Monatsschr Pharm. 1988;11(10):331–6.

56. Tack J., Müller-Lissner S., Stanghellini V., Boeckxstaens G., Kamm M.A., Simren M., et al. Diagnosis and treatment of chronic constipation — a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710. DOI: 10.1111/j.1365-2982.2011.01709.x

57. Ivashkin V.T., Alekseyenko S.A., Kolesova T.A., Korochanskaya N.V., Poluektova Y.A., Simanenkov V.I., et al. The resolution of Advisory council on diagnostics and treatment of the functional gastrointestinal diseases. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(4):129–30 (In Russ.). DOI: 10.22416/1382-4376-2016-26-4-129-130

58. Miller L.E., Tennilä J., Ouwehand A.C. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014;7:241–8. DOI: 10.2147/CEG.S58952

59. Mueller-Lissner S., Kamm M.A., Wald A., Hinkel U., Koehler U., Richter E., et al. Multicenter, 4-week, doubleblind, randomized, placebo-controlledtrial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897–903. DOI: 10.1038/ajg.2010.41.

60. Bengtsson M., Ohlsson B. Psychological well-being and symptoms in women with chronic constipation treated with sodium picosulphate. Gastroenterol Nurs. 2005;28(1):3– 12. DOI: 10.1097/00001610-200501000-00002

61. Sheptulin A.A. Prucalopride in treatment of functional chronic constipation. Rus J Gastroenterol Hepatol Coloproctol. 2012;22(1):9–13 (In Russ.).

62. Sajid M.S., Hebbar M., Baig M.K., Li A., Philipose Z. Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials. J Neurogastroenterol Motil. 2016; 22(3):412–22. DOI: 10.5056/jnm16004

63. Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225–46. DOI: 10.1177/030006059702500501

64. Zhong Y.Q., Zhu J., Guo J.-N., Yan R., Li H.-J., Lin Y.-H., et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndromе. Zhonghua Nei Ke Za Zhi. 2007;46(11):899–902.

65. Ivashkin V.T., Sheptulin A.A., Poluektova Ye.A., Reykhart D.V., Belostotsky A.V., Drozdova A.A., Arnautov V.S. Potential of «7×7» (7 symptoms per 7 days) questionnaire in assessment of symptom dynamics of functional dyspepsia and irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(3):24 (In Russ.). DOI: 10.22416/1382-4376-2016-26-3-24-33

66. Ivashkin V.T., Poluektova Y.A., Reykhart D.V., Shifrin O.S., Beniashvili A.G., Lyashenko O.S., Belostotsky A.V. Efficacy of drugs most commonly prescribed at functional gastrointestinal diseases (functional dyspepsia syndrome and irritable bowel syndrome) observational study results. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(4):7–14 )In Russ.). DOI: 10.22416/1382-4376-2016-26-4-14-23

67. Ottillinger B., Storr M., Malfertheiner P., Allescher H.D. STW 5 (Iberogast®) — a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3–4):65–72. DOI: 10.1007/s10354-012-0169-x

68. Sheptulin A.A., Kaybysheva V.O. Efficacy of the herbal preparation STW 5 in multi-target therapy of functional dyspepsia. Rus J Gastroenterol Hepatol Coloproctol. 2015; 25(5):101–6 (In Russ).

69. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Alekseyeva O.P., Baranskaya Y.K., Ivashkin K.V., et al. The resolution of Advisory council “How to improve treatment results functional dyspepsia and irritable bowel syndrome”? Rus J Gastroenterol Hepatol Coloproctol. 2016;26(2):101–4 (In Russ.). DOI: 10.22416/1382-4376-2016-26-2-101-104

70. Avalueva E.B., Adasheva T.V., Babaeva A.R., Burdina E.G., Kireeva N.V., Lenskaya L.G. et al. Kolofort efficacy and safety in irritable bowel syndrome: results of multi-centre double-blinded placebo-controlled randomised clinical trial. Gastroenterology. 2014; 1:36-43.

71. Maev I.V., Samsonov A.A., Yashina A.V., Kazyulin A.N., Shestakov V.A. Clinical efficacy and safety of irritable bowel syndrome treatment regimens (comparative trial data). Consilium Medicum, 2016; 18(8):19-26.

72. Ivashkin V.T., Poluektova E.A., Glazunov A.B., Putilovskiy M.A. Epstein O.I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC. Gastoenterology. 2019;20(1):2. DOI: 10.1186/s12876-019-1143-5

73. Xie C., Tang Y., Wang Y., Yu T., Wang Y., Jiang L., Lin L. Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis. PLoS One. 2015;10(8):e0127815.eCollection 2015. DOI: 10.1371/journal.pone.0127815

74. Bundeff A.W., Woodis C.B. Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome. The Annals of pharmacotherapy. 2014; 48(6):777– 84. DOI: 10.1177/1060028014528151

75. Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. New York: D Appleton and company, 1892.

76. Creed F. Relationship between IBS and psychiatric disorder. Irritable bowel syndrome. Ed. M. Camilleri, R. C. Spiller. 2002;45–54.

77. Dekel R., Drossman D.A., Sperber A.D. The use of psychotropic drugs in irritable bowel syndrome. Expert OpinInvestig Drugs. 2013;22(3):329–39. DOI: 10.1517/13543784.2013.761205

78. Hausteiner-Wiehle C., Henningsen P. Irritable bowel syndrome: Relations with functional, mental, and somatoform disorders. World J Gastroenterol. 2014;20(20):6024– 30. DOI: 10.3748/wjg.v20.i20.6024

79. Meerveld B.G.-V., Moloney R.D., Johnson A.C., Vicario M. Mechanisms of stress-induced visceral pain: implications in irritable bowel syndrome. J Neuroendocrinol. 2016;28(8). DOI: 10.1111/jne.12361

80. Pae C.U., Lee S.J., Han C., Patkar A.A., Masand P.S. Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert OpinInvestig Drugs. 2013;22(5):565–72. DOI: 10.1517/13543784.2013.782392

81. Annaházi A., Róka R., Rosztóczy A., Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–43. DOI: 10.3748/wjg.v20.i20.6031